Charles E. Hamner, Jr., Pd.D., the second president and CEO of the North Carolina Biotechnology Center and a longtime advocate for life sciences in the state, has received the 2024 High Flyer Champion ...

Come gain and share insights while growing your network in NC's ag tech community. This event is free for WIA members, but open to all. Thank you to Syngenta for sponsoring the Fall meet-up.

Radiopharmaceuticals, once a very niche drug class, are now on the brink of transforming cancer treatment and diagnostics, and North Carolina is at the heart of this change. These radioactive drugs ...

The Triangle is known as a hotbed for innovation, thanks in large part to the partnerships between multiple stakeholders, including universities, investors and ecosystem support organizations. In that ...

David Reeser is one of the millions of Americans whose life has been changed by the ever-evolving, fast-growing epidemic of ...

SCHOTT Pharma USA, Inc., part of SHOTT Pharma AG, a global specialty glass manufacturer based in Germany, plans to invest $371 million over the next five years to build a new production facility in ...

The North Carolina Biotechnology Center was saddened to learn that Philip Benfey, Ph.D., an inspiring and pioneering plant geneticist and entrepreneur, passed away on Sept. 26 at the age of 70. Benfey ...

Durham-based EydisBio Inc. has received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for EYD-001, a treatment for systemic sclerosis. This rare and debilitating ...

Jude Samulski calls genome editing “the next wave of technology to feed the world.” Samulski contributed $3 million to create the Roberts and Mikhail Distinguished Chair in Plant Genome Editing, an ...

Locus Biosciences is a fast-emerging North Carolina biotechnology company that’s about to get a lot faster at unfolding its Pac-Man-like genetic tricks to whack drug-resistant bacteria. The Research ...

Research Triangle Park-based Opus Genetics, a clinical-stage gene therapy company devoted to treating inherited retinal diseases, has been acquired by a small ophthalmic biopharmaceutical firm with ...